目的 分析2015—2017年福州市第二医院铜绿假单胞菌的分布及耐药性，为临床合理使用抗菌药物提供参考。方法 收集福州市第二医院2015—2017年临床分离的943株铜绿假单胞菌，对其标本来源分布、科室分布和耐药性进行分析。结果 共分离出943株铜绿假单胞菌，下呼吸道标本和伤口分泌物分别占50.2%、35.6%；科室分布以骨科（29.5%）最多，其次为呼吸内科（13.8%）和ICU（10.8%）。各年耐药率、菌株分离率总体呈下降趋势。铜绿假单胞菌对氨曲南的耐药率最高，达25.7%，对亚胺培南和美洛培南的耐药率分别为13.9%、9.1%，对阿米卡星的耐药率最低，为2.1%。骨科铜绿假单胞菌对亚胺培南（2.5%）和美洛培南（1.8%）仍然十分敏感。但呼吸内科和ICU的铜绿假单胞菌对亚胺培南和美罗培南的耐药率已经高达30%、20%。结论 应加强细菌耐药监测，采取有效措施控制耐药菌株传播，对延缓泛耐药铜绿假单胞菌的出现和防止水平传播将起到重要作用。

Objective To analyze the distribution and drug resistance of Pseudomonas aeruginosa in Fuzhou Second Hospital from 2015 to 2017, and to provide reference for rational use of antibiotics in clinic. Methods 943 Strains of P. aeruginosa isolated clinically in Fuzhou Second Hospital from 2015 to 2017 were collected, and source distribution, department distribution, and drug resistance were analyzed. Results Among the 943 specimens of P. aeruginosa, most of them were isolated from lower respiratory tract specimens (50.2%) and wound secretions 35.6%. Patients in Department of Orthopedics (29.5%) took the higher proportion, followed by 13.8% in Department of Respiratory Medicine and 10.8% in the ICU. The drug resistance rate and strain isolation rate showed a decreasing trend in all years. The resistance rate of P. aeruginosa against aztreonam was up to 25.7%, and the drug resistance rates of imipenem and meropenem were 13.9% and 9.1%, while the resistance rate of amikacin was the lowest (2.1%). P. aeruginosa in Department of Orthopedics was still very sensitive to imipenem (2.5%) and meropenem (1.8%). However, the resistance rates of P. aeruginosa in Department of Respiratory Medicine and ICU to imipenem and meropenem have been as high as 30% and 20%. Conclusion The monitoring of bacterial resistance should be strengthened and effective measures should be taken to control the spread of resistant strains, which will play an important role in delaying the emergence of pan-resistant P. aeruginosa and preventing horizontal transmission.